Manila Times Business
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
- 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial - - 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML - - High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing - - Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively - - 12-month survival rate, remission rates, MRD negativity,
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Kuwait reopens airspace after Iranian attacks: civil aviation body
Just now
Safe Pro Contracted to Provide U.S. Army Edge AI Operational Support for Airfield Exercise, Expanding its Role in Force Protection Applications
Just now
HERE WeGo brings real-time traffic intel to soccer fans across North America
Just now
Michelin | Disclosure of the total number of voting rights and of the number of shares making up the Company’s capital
Just now